Inglese

The data table (n=44 variables) contains information about AREDS participants' use (e.g. type, frequency, dose, duration) of non-steroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen, acetaminophen, naproxen). Data were collected at in-clinic visits starting in October 2004. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.

19 moduli  
  1. StudyEvent: NEI Age-Related Eye Disease Study (AREDS)
    1. Eligibility Criteria
    2. The data table (n=142 variables) contains AMD and cataract phenotype information, medical history and socio-demographic information drawn from several data sets (e.g. enrollment_randomization, amdlensphenotype, followup), plus a unique patient identifier (ID2) for participants with a genetic specimen (to be found only in GENSPECPHENOTYPE and GENSPECFUNDUSLENS [pht000376] tables). Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Other disease information (e.g. diabetes, cancer, angina), medical information (e.g. BMI, blood pressure) and smoking status are also included annually throughout follow-up.
    3. The data table (n=12 variables) contains information about the occurrence of adverse events during the AREDS clinical trial, e.g. type of adverse event, severity, primary ICD9 code, outcome, potential relationship to study drug, timing, and treatment. Data were collected through the clinical trial and for the first 6 months of the natural history follow-up immediately after the clinical trial concluded. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    4. The data table (n=25 variables) contains detailed information about cataract phenotypes (n=23 variables) as well as final AMD phenotype (n=1 variable), and patient ID. Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    5. The data table (n=56 variables) contains information about AREDS participants' dietary intake of alcohol, amino acids, carbohydrates, fiber, poly- and monounsaturated fatty acids, proteins, vitamins and minerals. Participants' glycemic index and glycemic load are also included. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    6. The data table (n=102 variables) contains AREDS treatment assignment, basic socio-demographic characteristics and baseline medical history for AREDS participants. Medical history information includes eye disease information such as AMD Category, visual acuity, and past ophthalmic treatments (e.g. cataract surgery, laser treatment), as well as information about the presence/absence of other diseases (e.g. angina, arthritis, cancer, diabetes, high blood pressure), use of prescribed drugs for disease management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), intake of vitamins and minerals, and smoking history. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    7. The data table (n=83 variables) contains information obtained at follow-up visits during the AREDS clinical trial (every six months following randomization), annually in person during the natural history follow-up, and via phone between annual in-person visits. Variables include information about AREDS participants' ophthalmic medical history (e.g. cataract or other eye surgery, laser treatment for AMD, retinal repair, capsulotomy, presence/absence of lens, glaucoma, and visual acuity) and general medical information, including new diagnoses of cancer, heart disease, stroke, and peripheral vascular disease, disease history of angina and high blood pressure, current disease status of diabetes, arthritis, and gout, use of prescribed drugs for disease treatment or management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), and smoking behavior. For version 3 release of the study, visual acuity data of the right eye have been added for odd-numbered visits. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    8. The data table (n=49 variables) contains information from AREDS participants' fundus photographs, including presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy. In addition, information on photocoagulation (PC) treatment for AMD SRNV is included, as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    9. The data table (n=62) contains information only for AREDS participants who have a genetic specimen. A unique patient identifier (ID2 field) for these participants (to be found only in GENSPECPHENOTYPE [pht000001.v2.p1] and GENSPECFUNDUSLENS data tables) is included instead of the patient identifier used for data tables with all participants (ID field). Information about fundus and lens characteristics are included as follows - fundus: presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy; lens: degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. In addition, information on photocoagulation (PC) treatment for AMD is included as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data.
    10. The data table (n=6 variables) contains information about AREDS participant hospitalizations (e.g. reason, time from randomization, duration, primary ICD9 code) during the entire study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    11. The data table (n=21 variables) contains information from AREDS participants' lens photographs, including degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    12. The data table (n=7 variables) contains information about AREDS participant deaths (e.g. cause, time from randomization) during the entire study. A search using the National Death Index (NDI) yielded additional deaths not identified during the study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    13. The data table (n=44 variables) contains information about AREDS participants' use (e.g. type, frequency, dose, duration) of non-steroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen, acetaminophen, naproxen). Data were collected at in-clinic visits starting in October 2004. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    14. The data table (n=16 variables) contains information about AREDS participants' general vision status (e.g. general vision score, ocular pain score, VFQ overall score), and its effect on participants' behavior (e.g. near and distant activities, social activities, driving, mental health score) as obtained through the VFQ-25 questionnaire. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    15. Subject - Consent Information
    16. Subject - Sample Mapping (including mapping to Coriell IDs)
    17. The data table (n=2 variables) contains information on subjects' annual exposure to sunlight (hours; April through September).
    18. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
    19. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
pht000381
Descrizione

pht000381

DUMMY ID NUMBER
Descrizione

ID2

Tipo di dati

string

Alias
UMLS CUI [1,1]
C2348585
STUDY VISIT NUMBER AT WHICH NSAID DATA WAS COLLECTED (ALL PARTICIPANTS)
Descrizione

VISNO

Tipo di dati

text

Alias
UMLS CUI [1,1]
C3274381
UMLS CUI [1,2]
C0545082
UMLS CUI [1,3]
C0003211
UMLS CUI [1,4]
C0010995
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
TAKEN AN NSAID (EXCEPT COX-2 INHIBITORS) IN LAST 10 YEARS FOR AT LEAST 5X/WEEK FOR AT LEAST 3 MONTHS (ALL PARTICIPANTS)
Descrizione

NSAIDS

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0205272
UMLS CUI [1,2]
C0003211
UMLS CUI [1,3]
C1444637
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
LOW-DOSE BABY ASPIRIN (81MG) (ALL PARTICIPANTS)
Descrizione

BABYASP

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0004057
UMLS CUI [1,2]
C0205251
UMLS CUI [1,3]
C0178602
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
LOW-DOSE BABY ASPIRIN PILLS/DAY (ALL PARTICIPANTS)
Descrizione

BABYPILS

Tipo di dati

text

Unità di misura
  • Pills/Day
Alias
UMLS CUI [1,1]
C0004057
UMLS CUI [1,2]
C0205251
UMLS CUI [1,3]
C0178602
UMLS CUI [1,4]
C0750480
UMLS CUI [1,5]
C0994475
UMLS CUI [1,6]
C2348070
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
Pills/Day
REGULAR STRENGTH ASPIRIN (ALL PARTICIPANTS)
Descrizione

REGASP

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0004057
UMLS CUI [1,2]
C0205272
UMLS CUI [1,3]
C0442821
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
ANACIN (400MG) (ALL PARTICIPANTS)
Descrizione

ANACIN

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0004057
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
ANACIN PILLS/DAY (ALL PARTICIPANTS)
Descrizione

ANACNPIL

Tipo di dati

text

Unità di misura
  • Pills/Day
Alias
UMLS CUI [1,1]
C0004057
UMLS CUI [1,2]
C2348070
UMLS CUI [1,3]
C0750480
UMLS CUI [1,4]
C0994475
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
Pills/Day
BAYER/BUFFERIN/ECOTRIN (325 MG) (ALL PARTICIPANTS)
Descrizione

BAYER

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0004057
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
BAYER/BUFFERIN/ECOTRIN PILLS/DAY (ALL PARTICIPANTS)
Descrizione

BAYRPILS

Tipo di dati

text

Unità di misura
  • Pills/Day
Alias
UMLS CUI [1,1]
C0004057
UMLS CUI [1,2]
C2348070
UMLS CUI [1,3]
C0750480
UMLS CUI [1,4]
C0994475
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
Pills/Day
OTHER REGULAR-STRENGTH ASPIRIN (ALL PARTICIPANTS)
Descrizione

OTHASP

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0205394
UMLS CUI [1,2]
C0004057
UMLS CUI [1,3]
C0205272
UMLS CUI [1,4]
C0442821
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
OTHER REGULAR-STRENGTH ASPIRIN NAME (ALL PARTICIPANTS)
Descrizione

OTHASPSP

Tipo di dati

string

Alias
UMLS CUI [1,1]
C0205394
UMLS CUI [1,2]
C0004057
UMLS CUI [1,3]
C0205272
UMLS CUI [1,4]
C0442821
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
OTHER REGULAR-STRENGTH ASPIRIN PILLS/DAY (ALL PARTICIPANTS)
Descrizione

OTHASPIL

Tipo di dati

text

Unità di misura
  • Pills/Day
Alias
UMLS CUI [1,1]
C0205394
UMLS CUI [1,2]
C0004057
UMLS CUI [1,3]
C0205272
UMLS CUI [1,4]
C0442821
UMLS CUI [1,5]
C0750480
UMLS CUI [1,6]
C0994475
UMLS CUI [1,7]
C2348070
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
Pills/Day
EXTRA/MAXIMUM STRENGTH ASPIRIN (500 MG) (ALL PARTICIPANTS)
Descrizione

MAXIMUM

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0004057
UMLS CUI [1,2]
C1524062
UMLS CUI [1,3]
C0806909
UMLS CUI [1,4]
C0442821
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
EXTRA/MAXIMUM STRENGTH ASPIRIN PILLS/DAY (ALL PARTICIPANTS)
Descrizione

MAXPILS

Tipo di dati

text

Unità di misura
  • Pills/Day
Alias
UMLS CUI [1,1]
C0004057
UMLS CUI [1,2]
C1524062
UMLS CUI [1,3]
C0806909
UMLS CUI [1,4]
C0442821
UMLS CUI [1,5]
C2348070
UMLS CUI [1,6]
C0750480
UMLS CUI [1,7]
C0994475
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
Pills/Day
EXCEDRIN EXTRA STRENGTH/MIGRAINE (250 MG ASPIRIN; 250 MG ACETAMINOPHEN) (ALL PARTICIPANTS)
Descrizione

EXCEDRIN

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0720328
UMLS CUI [1,2]
C0442821
UMLS CUI [2,1]
C0149931
UMLS CUI [3,1]
C0681850
UMLS CUI [3,2]
C0444868
EXCEDRIN EXTRA STRENGTH/MIGRAINE PILLS/DAY (ALL PARTICIPANTS)
Descrizione

EXCEDPIL

Tipo di dati

text

Unità di misura
  • Pills/Day
Alias
UMLS CUI [1,1]
C0720328
UMLS CUI [1,2]
C0442821
UMLS CUI [1,3]
C0149931
UMLS CUI [1,4]
C0750480
UMLS CUI [1,5]
C0994475
UMLS CUI [1,6]
C2348070
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
Pills/Day
VANQUISH (227 MG ASPIRIN; 194 MG ACETAMINOPHEN) (ALL PARTICIPANTS)
Descrizione

VANQUISH

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0004057
UMLS CUI [1,2]
C0000970
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
VANQUISH PILLS/DAY (ALL PARTICIPANTS)
Descrizione

VANQPILS

Tipo di dati

text

Unità di misura
  • Pills/Day
Alias
UMLS CUI [1,1]
C0000970
UMLS CUI [1,2]
C0004057
UMLS CUI [1,3]
C0750480
UMLS CUI [1,4]
C0994475
UMLS CUI [1,5]
C2348070
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
Pills/Day
IBUPROFEN (200 MG) (ALL PARTICIPANTS)
Descrizione

IBUPROF

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0020740
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
IBUPROFEN PILLS/DAY (ALL PARTICIPANTS)
Descrizione

IBUPRPIL

Tipo di dati

text

Unità di misura
  • Pills/Day
Alias
UMLS CUI [1,1]
C0020740
UMLS CUI [1,2]
C0750480
UMLS CUI [1,3]
C0994475
UMLS CUI [1,4]
C2348070
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
Pills/Day
NAPROXEN (ALL PARTICIPANTS)
Descrizione

NAPROXEN

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0027396
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
ALEVE (220 MG) (ALL PARTICIPANTS)
Descrizione

ALEVE

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0718343
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
ALEVE PILLS/DAY (ALL PARTICIPANTS)
Descrizione

ALEVEPIL

Tipo di dati

text

Unità di misura
  • Pills/Day
Alias
UMLS CUI [1,1]
C0718343
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
Pills/Day
ANAPROX DS (550 MG) (ALL PARTICIPANTS)
Descrizione

ANAPROX

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0699095
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
ANAPROX DS PILLS/DAY (ALL PARTICIPANTS)
Descrizione

ANAPRPIL

Tipo di dati

text

Unità di misura
  • Pills/Day
Alias
UMLS CUI [1,1]
C0699095
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
Pills/Day
NAPROSYN/NAPRELAN (375 MG) (ALL PARTICIPANTS)
Descrizione

NAPRO375

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0700017
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
NAPROSYN/NAPRELAN (375 MG) PILLS/DAY (ALL PARTICIPANTS)
Descrizione

NAP375PL

Tipo di dati

text

Unità di misura
  • Pills/Day
Alias
UMLS CUI [1,1]
C0700017
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
Pills/Day
NAPROSYN/NAPRELAN (500 MG) (ALL PARTICIPANTS)
Descrizione

NAPRO500

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0700017
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
NAPROSYN/NAPRELAN (500MG) PILLS/DAY (ALL PARTICIPANTS)
Descrizione

NAP500PL

Tipo di dati

text

Unità di misura
  • Pills/Day
Alias
UMLS CUI [1,1]
C0700017
UMLS CUI [1,2]
C0750480
UMLS CUI [1,3]
C0994475
UMLS CUI [1,4]
C2348070
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
Pills/Day
OTHER NAPROXEN (ALL PARTICIPANTS)
Descrizione

OTHNAP

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0205394
UMLS CUI [1,2]
C0027396
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
OTHER NAPROXEN NAME (ALL PARTICIPANTS)
Descrizione

OTHNAPSP

Tipo di dati

string

Alias
UMLS CUI [1,1]
C0205394
UMLS CUI [1,2]
C0027396
UMLS CUI [1,3]
C0027365
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
OTHER NAPROXEN PILLS/DAY (ALL PARTICIPANTS)
Descrizione

OTHNAPPL

Tipo di dati

text

Unità di misura
  • Pills/Day
Alias
UMLS CUI [1,1]
C0205394
UMLS CUI [1,2]
C0027396
UMLS CUI [1,3]
C0750480
UMLS CUI [1,4]
C0994475
UMLS CUI [1,5]
C2348070
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
Pills/Day
PIROXICAM/FELDENE (10 MG) (ALL PARTICIPANTS)
Descrizione

PIROX10

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0031990
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
PIROXICAM/FELDENE (10 MG) PILLS/DAY (ALL PARTICIPANTS)
Descrizione

PIRX10PL

Tipo di dati

text

Unità di misura
  • Pills/Day
Alias
UMLS CUI [1,1]
C0031990
UMLS CUI [1,2]
C0750480
UMLS CUI [1,3]
C0994475
UMLS CUI [1,4]
C2348070
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
Pills/Day
PIROXICAM/FELDENE (20 MG) (ALL PARTICIPANTS)
Descrizione

PIROX20

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0031990
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
PIROXICAM/FELDENE (20 MG) PILLS/DAY (ALL PARTICIPANTS)
Descrizione

PIRX20PL

Tipo di dati

text

Unità di misura
  • Pills/Day
Alias
UMLS CUI [1,1]
C0031990
UMLS CUI [1,2]
C0750480
UMLS CUI [1,3]
C0994475
UMLS CUI [1,4]
C2348070
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
Pills/Day
ACETAMINOPHEN (PILLS/DAY) (ALL PARTICIPANTS)
Descrizione

ACETAPIL

Tipo di dati

text

Unità di misura
  • Pills/Day
Alias
UMLS CUI [1,1]
C0000970
UMLS CUI [1,2]
C0750480
UMLS CUI [1,3]
C0994475
UMLS CUI [1,4]
C2348070
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
Pills/Day
OTHER NSAID (ALL PARTICIPANTS)
Descrizione

OTHNSAID

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0205394
UMLS CUI [1,2]
C0003211
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
OTHER NSAID NAME (ALL PARTICIPANTS)
Descrizione

OTHNSASP

Tipo di dati

string

Alias
UMLS CUI [1,1]
C0205394
UMLS CUI [1,2]
C0003211
UMLS CUI [1,3]
C0027365
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
OTHER NSAID PILLS/DAY (ALL PARTICIPANTS)
Descrizione

OTHNSAPL

Tipo di dati

text

Unità di misura
  • Pills/Day
Alias
UMLS CUI [1,1]
C0205394
UMLS CUI [1,2]
C0003211
UMLS CUI [1,3]
C0750480
UMLS CUI [1,4]
C0994475
UMLS CUI [1,5]
C2348070
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
Pills/Day
HOW LONG ON NSAID AT LEAST 5 TIMES/WEEK (ALL PARTICIPANTS)
Descrizione

HOWLONG

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0449238
UMLS CUI [1,2]
C0003211
UMLS CUI [1,3]
C0205272
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
ACETAMINOPHEN (500 MG) (ALL PARTICIPANTS)
Descrizione

ACETAM

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0000970
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
YEARS FROM RANDOMIZATION TO DATE OF STUDY VISIT WHERE NSAID DATA WAS COLLECTED (ALL PARTICIPANTS)
Descrizione

NSAIDSTIME

Tipo di dati

float

Unità di misura
  • years
Alias
UMLS CUI [1,1]
C0439234
UMLS CUI [1,2]
C0034656
UMLS CUI [1,3]
C0008972
UMLS CUI [1,4]
C1320303
UMLS CUI [1,5]
C0003211
UMLS CUI [1,6]
C0010995
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
years
Ritorna all'inizio della pagina

Similar models

The data table (n=44 variables) contains information about AREDS participants' use (e.g. type, frequency, dose, duration) of non-steroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen, acetaminophen, naproxen). Data were collected at in-clinic visits starting in October 2004. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.

19 moduli
  1. StudyEvent: NEI Age-Related Eye Disease Study (AREDS)
    1. Eligibility Criteria
    2. The data table (n=142 variables) contains AMD and cataract phenotype information, medical history and socio-demographic information drawn from several data sets (e.g. enrollment_randomization, amdlensphenotype, followup), plus a unique patient identifier (ID2) for participants with a genetic specimen (to be found only in GENSPECPHENOTYPE and GENSPECFUNDUSLENS [pht000376] tables). Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Other disease information (e.g. diabetes, cancer, angina), medical information (e.g. BMI, blood pressure) and smoking status are also included annually throughout follow-up.
    3. The data table (n=12 variables) contains information about the occurrence of adverse events during the AREDS clinical trial, e.g. type of adverse event, severity, primary ICD9 code, outcome, potential relationship to study drug, timing, and treatment. Data were collected through the clinical trial and for the first 6 months of the natural history follow-up immediately after the clinical trial concluded. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    4. The data table (n=25 variables) contains detailed information about cataract phenotypes (n=23 variables) as well as final AMD phenotype (n=1 variable), and patient ID. Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    5. The data table (n=56 variables) contains information about AREDS participants' dietary intake of alcohol, amino acids, carbohydrates, fiber, poly- and monounsaturated fatty acids, proteins, vitamins and minerals. Participants' glycemic index and glycemic load are also included. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    6. The data table (n=102 variables) contains AREDS treatment assignment, basic socio-demographic characteristics and baseline medical history for AREDS participants. Medical history information includes eye disease information such as AMD Category, visual acuity, and past ophthalmic treatments (e.g. cataract surgery, laser treatment), as well as information about the presence/absence of other diseases (e.g. angina, arthritis, cancer, diabetes, high blood pressure), use of prescribed drugs for disease management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), intake of vitamins and minerals, and smoking history. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    7. The data table (n=83 variables) contains information obtained at follow-up visits during the AREDS clinical trial (every six months following randomization), annually in person during the natural history follow-up, and via phone between annual in-person visits. Variables include information about AREDS participants' ophthalmic medical history (e.g. cataract or other eye surgery, laser treatment for AMD, retinal repair, capsulotomy, presence/absence of lens, glaucoma, and visual acuity) and general medical information, including new diagnoses of cancer, heart disease, stroke, and peripheral vascular disease, disease history of angina and high blood pressure, current disease status of diabetes, arthritis, and gout, use of prescribed drugs for disease treatment or management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), and smoking behavior. For version 3 release of the study, visual acuity data of the right eye have been added for odd-numbered visits. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    8. The data table (n=49 variables) contains information from AREDS participants' fundus photographs, including presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy. In addition, information on photocoagulation (PC) treatment for AMD SRNV is included, as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    9. The data table (n=62) contains information only for AREDS participants who have a genetic specimen. A unique patient identifier (ID2 field) for these participants (to be found only in GENSPECPHENOTYPE [pht000001.v2.p1] and GENSPECFUNDUSLENS data tables) is included instead of the patient identifier used for data tables with all participants (ID field). Information about fundus and lens characteristics are included as follows - fundus: presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy; lens: degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. In addition, information on photocoagulation (PC) treatment for AMD is included as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data.
    10. The data table (n=6 variables) contains information about AREDS participant hospitalizations (e.g. reason, time from randomization, duration, primary ICD9 code) during the entire study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    11. The data table (n=21 variables) contains information from AREDS participants' lens photographs, including degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    12. The data table (n=7 variables) contains information about AREDS participant deaths (e.g. cause, time from randomization) during the entire study. A search using the National Death Index (NDI) yielded additional deaths not identified during the study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    13. The data table (n=44 variables) contains information about AREDS participants' use (e.g. type, frequency, dose, duration) of non-steroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen, acetaminophen, naproxen). Data were collected at in-clinic visits starting in October 2004. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    14. The data table (n=16 variables) contains information about AREDS participants' general vision status (e.g. general vision score, ocular pain score, VFQ overall score), and its effect on participants' behavior (e.g. near and distant activities, social activities, driving, mental health score) as obtained through the VFQ-25 questionnaire. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    15. Subject - Consent Information
    16. Subject - Sample Mapping (including mapping to Coriell IDs)
    17. The data table (n=2 variables) contains information on subjects' annual exposure to sunlight (hours; April through September).
    18. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
    19. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
pht000381
ID2
Item
DUMMY ID NUMBER
string
C2348585 (UMLS CUI [1,1])
Item
STUDY VISIT NUMBER AT WHICH NSAID DATA WAS COLLECTED (ALL PARTICIPANTS)
text
C3274381 (UMLS CUI [1,1])
C0545082 (UMLS CUI [1,2])
C0003211 (UMLS CUI [1,3])
C0010995 (UMLS CUI [1,4])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
VISNO
Code List
STUDY VISIT NUMBER AT WHICH NSAID DATA WAS COLLECTED (ALL PARTICIPANTS)
CL Item
Baseline visit (00)
C1442488 (UMLS CUI [1,1])
C0545082 (UMLS CUI [1,2])
CL Item
0.5-year (01)
C0444500 (UMLS CUI [1,1])
C0439234 (UMLS CUI [1,2])
CL Item
1-year (02)
C0205447 (UMLS CUI [1,1])
C0439234 (UMLS CUI [1,2])
CL Item
1.5-years (03)
C0439234 (UMLS CUI [1,1])
CL Item
2-years (04)
C0205448 (UMLS CUI [1,1])
C0439234 (UMLS CUI [1,2])
CL Item
2.5-years (05)
C3844011 (UMLS CUI [1,1])
C0439234 (UMLS CUI [1,2])
CL Item
3-years (06)
C0439234 (UMLS CUI [1,1])
C0205437 (UMLS CUI [1,2])
CL Item
3.5-years (07)
C0439234 (UMLS CUI [1,1])
CL Item
4-years (08)
C0205450 (UMLS CUI [1,1])
C0439234 (UMLS CUI [1,2])
CL Item
4.5-years (09)
C0439234 (UMLS CUI [1,1])
CL Item
5-years (10)
C0205451 (UMLS CUI [1,1])
C0439234 (UMLS CUI [1,2])
CL Item
5.5-years (11)
C0439234 (UMLS CUI [1,1])
CL Item
6-years (12)
C0205452 (UMLS CUI [1,1])
C0439234 (UMLS CUI [1,2])
CL Item
6.5-years (13)
C0439234 (UMLS CUI [1,1])
CL Item
7-years (14)
C0205453 (UMLS CUI [1,1])
C0439234 (UMLS CUI [1,2])
CL Item
7.5-years (15)
C0439234 (UMLS CUI [1,1])
CL Item
8-years (16)
C0205454 (UMLS CUI [1,1])
C0439234 (UMLS CUI [1,2])
CL Item
8.5-years (17)
C0439234 (UMLS CUI [1,1])
CL Item
9-years (18)
C0439234 (UMLS CUI [1,1])
CL Item
9.5-years (19)
C0439234 (UMLS CUI [1,1])
CL Item
10-years (20)
C0439234 (UMLS CUI [1,1])
CL Item
10.5-years (21)
C0439234 (UMLS CUI [1,1])
CL Item
11-years (22)
C0439234 (UMLS CUI [1,1])
CL Item
11.5-years (23)
C0439234 (UMLS CUI [1,1])
CL Item
12-years (24)
C0439234 (UMLS CUI [1,1])
CL Item
12.5-years (25)
C0439234 (UMLS CUI [1,1])
CL Item
13-years (26)
C0439234 (UMLS CUI [1,1])
Item
TAKEN AN NSAID (EXCEPT COX-2 INHIBITORS) IN LAST 10 YEARS FOR AT LEAST 5X/WEEK FOR AT LEAST 3 MONTHS (ALL PARTICIPANTS)
text
C0205272 (UMLS CUI [1,1])
C0003211 (UMLS CUI [1,2])
C1444637 (UMLS CUI [1,3])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
NSAIDS
Code List
TAKEN AN NSAID (EXCEPT COX-2 INHIBITORS) IN LAST 10 YEARS FOR AT LEAST 5X/WEEK FOR AT LEAST 3 MONTHS (ALL PARTICIPANTS)
CL Item
No (N)
C1298908 (UMLS CUI [1,1])
CL Item
Yes (Y)
C1705108 (UMLS CUI [1,1])
Item
LOW-DOSE BABY ASPIRIN (81MG) (ALL PARTICIPANTS)
text
C0004057 (UMLS CUI [1,1])
C0205251 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
BABYASP
Code List
LOW-DOSE BABY ASPIRIN (81MG) (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
BABYPILS
Item
LOW-DOSE BABY ASPIRIN PILLS/DAY (ALL PARTICIPANTS)
text
C0004057 (UMLS CUI [1,1])
C0205251 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C0750480 (UMLS CUI [1,4])
C0994475 (UMLS CUI [1,5])
C2348070 (UMLS CUI [1,6])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
Item
REGULAR STRENGTH ASPIRIN (ALL PARTICIPANTS)
text
C0004057 (UMLS CUI [1,1])
C0205272 (UMLS CUI [1,2])
C0442821 (UMLS CUI [1,3])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
REGASP
Code List
REGULAR STRENGTH ASPIRIN (ALL PARTICIPANTS)
CL Item
No (N)
C1298908 (UMLS CUI [1,1])
CL Item
Yes (Y)
C1705108 (UMLS CUI [1,1])
Item
ANACIN (400MG) (ALL PARTICIPANTS)
text
C0004057 (UMLS CUI [1,1])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
ANACIN
Code List
ANACIN (400MG) (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
ANACNPIL
Item
ANACIN PILLS/DAY (ALL PARTICIPANTS)
text
C0004057 (UMLS CUI [1,1])
C2348070 (UMLS CUI [1,2])
C0750480 (UMLS CUI [1,3])
C0994475 (UMLS CUI [1,4])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
Item
BAYER/BUFFERIN/ECOTRIN (325 MG) (ALL PARTICIPANTS)
text
C0013227 (UMLS CUI [1,1])
C0004057 (UMLS CUI [1,2])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
BAYER
Code List
BAYER/BUFFERIN/ECOTRIN (325 MG) (ALL PARTICIPANTS)
CL Item
No (N)
C1298908 (UMLS CUI [1,1])
CL Item
Yes (Y)
C1705108 (UMLS CUI [1,1])
BAYRPILS
Item
BAYER/BUFFERIN/ECOTRIN PILLS/DAY (ALL PARTICIPANTS)
text
C0004057 (UMLS CUI [1,1])
C2348070 (UMLS CUI [1,2])
C0750480 (UMLS CUI [1,3])
C0994475 (UMLS CUI [1,4])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
Item
OTHER REGULAR-STRENGTH ASPIRIN (ALL PARTICIPANTS)
text
C0205394 (UMLS CUI [1,1])
C0004057 (UMLS CUI [1,2])
C0205272 (UMLS CUI [1,3])
C0442821 (UMLS CUI [1,4])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
OTHASP
Code List
OTHER REGULAR-STRENGTH ASPIRIN (ALL PARTICIPANTS)
CL Item
No (N)
C1298908 (UMLS CUI [1,1])
CL Item
Yes (Y)
C1705108 (UMLS CUI [1,1])
OTHASPSP
Item
OTHER REGULAR-STRENGTH ASPIRIN NAME (ALL PARTICIPANTS)
string
C0205394 (UMLS CUI [1,1])
C0004057 (UMLS CUI [1,2])
C0205272 (UMLS CUI [1,3])
C0442821 (UMLS CUI [1,4])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
OTHASPIL
Item
OTHER REGULAR-STRENGTH ASPIRIN PILLS/DAY (ALL PARTICIPANTS)
text
C0205394 (UMLS CUI [1,1])
C0004057 (UMLS CUI [1,2])
C0205272 (UMLS CUI [1,3])
C0442821 (UMLS CUI [1,4])
C0750480 (UMLS CUI [1,5])
C0994475 (UMLS CUI [1,6])
C2348070 (UMLS CUI [1,7])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
Item
EXTRA/MAXIMUM STRENGTH ASPIRIN (500 MG) (ALL PARTICIPANTS)
text
C0004057 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C0806909 (UMLS CUI [1,3])
C0442821 (UMLS CUI [1,4])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
MAXIMUM
Code List
EXTRA/MAXIMUM STRENGTH ASPIRIN (500 MG) (ALL PARTICIPANTS)
CL Item
No (N)
C1298908 (UMLS CUI [1,1])
CL Item
Yes (Y)
C1705108 (UMLS CUI [1,1])
MAXPILS
Item
EXTRA/MAXIMUM STRENGTH ASPIRIN PILLS/DAY (ALL PARTICIPANTS)
text
C0004057 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C0806909 (UMLS CUI [1,3])
C0442821 (UMLS CUI [1,4])
C2348070 (UMLS CUI [1,5])
C0750480 (UMLS CUI [1,6])
C0994475 (UMLS CUI [1,7])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
Item
EXCEDRIN EXTRA STRENGTH/MIGRAINE (250 MG ASPIRIN; 250 MG ACETAMINOPHEN) (ALL PARTICIPANTS)
text
C0720328 (UMLS CUI [1,1])
C0442821 (UMLS CUI [1,2])
C0149931 (UMLS CUI [2,1])
C0681850 (UMLS CUI [3,1])
C0444868 (UMLS CUI [3,2])
EXCEDRIN
Code List
EXCEDRIN EXTRA STRENGTH/MIGRAINE (250 MG ASPIRIN; 250 MG ACETAMINOPHEN) (ALL PARTICIPANTS)
CL Item
No (N)
C1298908 (UMLS CUI [1,1])
CL Item
Yes (Y)
C1705108 (UMLS CUI [1,1])
EXCEDPIL
Item
EXCEDRIN EXTRA STRENGTH/MIGRAINE PILLS/DAY (ALL PARTICIPANTS)
text
C0720328 (UMLS CUI [1,1])
C0442821 (UMLS CUI [1,2])
C0149931 (UMLS CUI [1,3])
C0750480 (UMLS CUI [1,4])
C0994475 (UMLS CUI [1,5])
C2348070 (UMLS CUI [1,6])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
Item
VANQUISH (227 MG ASPIRIN; 194 MG ACETAMINOPHEN) (ALL PARTICIPANTS)
text
C0004057 (UMLS CUI [1,1])
C0000970 (UMLS CUI [1,2])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
VANQUISH
Code List
VANQUISH (227 MG ASPIRIN; 194 MG ACETAMINOPHEN) (ALL PARTICIPANTS)
CL Item
No (N)
C1298908 (UMLS CUI [1,1])
CL Item
Yes (Y)
C1705108 (UMLS CUI [1,1])
VANQPILS
Item
VANQUISH PILLS/DAY (ALL PARTICIPANTS)
text
C0000970 (UMLS CUI [1,1])
C0004057 (UMLS CUI [1,2])
C0750480 (UMLS CUI [1,3])
C0994475 (UMLS CUI [1,4])
C2348070 (UMLS CUI [1,5])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
Item
IBUPROFEN (200 MG) (ALL PARTICIPANTS)
text
C0020740 (UMLS CUI [1,1])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
IBUPROF
Code List
IBUPROFEN (200 MG) (ALL PARTICIPANTS)
CL Item
No (N)
C1298908 (UMLS CUI [1,1])
CL Item
Yes (Y)
C1705108 (UMLS CUI [1,1])
IBUPRPIL
Item
IBUPROFEN PILLS/DAY (ALL PARTICIPANTS)
text
C0020740 (UMLS CUI [1,1])
C0750480 (UMLS CUI [1,2])
C0994475 (UMLS CUI [1,3])
C2348070 (UMLS CUI [1,4])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
Item
NAPROXEN (ALL PARTICIPANTS)
text
C0027396 (UMLS CUI [1,1])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
IBUPROF
Code List
NAPROXEN (ALL PARTICIPANTS)
CL Item
No (N)
C1298908 (UMLS CUI [1,1])
CL Item
Yes (Y)
C1705108 (UMLS CUI [1,1])
Item
ALEVE (220 MG) (ALL PARTICIPANTS)
text
C0718343 (UMLS CUI [1,1])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
IBUPROF
Code List
ALEVE (220 MG) (ALL PARTICIPANTS)
CL Item
No (N)
C1298908 (UMLS CUI [1,1])
CL Item
Yes (Y)
C1705108 (UMLS CUI [1,1])
ALEVEPIL
Item
ALEVE PILLS/DAY (ALL PARTICIPANTS)
text
C0718343 (UMLS CUI [1,1])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
Item
ANAPROX DS (550 MG) (ALL PARTICIPANTS)
text
C0699095 (UMLS CUI [1,1])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
IBUPROF
Code List
ANAPROX DS (550 MG) (ALL PARTICIPANTS)
CL Item
No (N)
C1298908 (UMLS CUI [1,1])
CL Item
Yes (Y)
C1705108 (UMLS CUI [1,1])
ANAPRPIL
Item
ANAPROX DS PILLS/DAY (ALL PARTICIPANTS)
text
C0699095 (UMLS CUI [1,1])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
Item
NAPROSYN/NAPRELAN (375 MG) (ALL PARTICIPANTS)
text
C0700017 (UMLS CUI [1,1])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
IBUPROF
Code List
NAPROSYN/NAPRELAN (375 MG) (ALL PARTICIPANTS)
CL Item
No (N)
C1298908 (UMLS CUI [1,1])
CL Item
Yes (Y)
C1705108 (UMLS CUI [1,1])
NAP375PL
Item
NAPROSYN/NAPRELAN (375 MG) PILLS/DAY (ALL PARTICIPANTS)
text
C0700017 (UMLS CUI [1,1])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
Item
NAPROSYN/NAPRELAN (500 MG) (ALL PARTICIPANTS)
text
C0700017 (UMLS CUI [1,1])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
IBUPROF
Code List
NAPROSYN/NAPRELAN (500 MG) (ALL PARTICIPANTS)
CL Item
No (N)
C1298908 (UMLS CUI [1,1])
CL Item
Yes (Y)
C1705108 (UMLS CUI [1,1])
NAP500PL
Item
NAPROSYN/NAPRELAN (500MG) PILLS/DAY (ALL PARTICIPANTS)
text
C0700017 (UMLS CUI [1,1])
C0750480 (UMLS CUI [1,2])
C0994475 (UMLS CUI [1,3])
C2348070 (UMLS CUI [1,4])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
Item
OTHER NAPROXEN (ALL PARTICIPANTS)
text
C0205394 (UMLS CUI [1,1])
C0027396 (UMLS CUI [1,2])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
IBUPROF
Code List
OTHER NAPROXEN (ALL PARTICIPANTS)
CL Item
No (N)
C1298908 (UMLS CUI [1,1])
CL Item
Yes (Y)
C1705108 (UMLS CUI [1,1])
OTHNAPSP
Item
OTHER NAPROXEN NAME (ALL PARTICIPANTS)
string
C0205394 (UMLS CUI [1,1])
C0027396 (UMLS CUI [1,2])
C0027365 (UMLS CUI [1,3])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
OTHNAPPL
Item
OTHER NAPROXEN PILLS/DAY (ALL PARTICIPANTS)
text
C0205394 (UMLS CUI [1,1])
C0027396 (UMLS CUI [1,2])
C0750480 (UMLS CUI [1,3])
C0994475 (UMLS CUI [1,4])
C2348070 (UMLS CUI [1,5])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
Item
PIROXICAM/FELDENE (10 MG) (ALL PARTICIPANTS)
text
C0031990 (UMLS CUI [1,1])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
IBUPROF
Code List
PIROXICAM/FELDENE (10 MG) (ALL PARTICIPANTS)
CL Item
No (N)
C1298908 (UMLS CUI [1,1])
CL Item
Yes (Y)
C1705108 (UMLS CUI [1,1])
PIRX10PL
Item
PIROXICAM/FELDENE (10 MG) PILLS/DAY (ALL PARTICIPANTS)
text
C0031990 (UMLS CUI [1,1])
C0750480 (UMLS CUI [1,2])
C0994475 (UMLS CUI [1,3])
C2348070 (UMLS CUI [1,4])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
Item
PIROXICAM/FELDENE (20 MG) (ALL PARTICIPANTS)
text
C0031990 (UMLS CUI [1,1])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
IBUPROF
Code List
PIROXICAM/FELDENE (20 MG) (ALL PARTICIPANTS)
CL Item
No (N)
C1298908 (UMLS CUI [1,1])
CL Item
Yes (Y)
C1705108 (UMLS CUI [1,1])
PIRX20PL
Item
PIROXICAM/FELDENE (20 MG) PILLS/DAY (ALL PARTICIPANTS)
text
C0031990 (UMLS CUI [1,1])
C0750480 (UMLS CUI [1,2])
C0994475 (UMLS CUI [1,3])
C2348070 (UMLS CUI [1,4])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
ACETAPIL
Item
ACETAMINOPHEN (PILLS/DAY) (ALL PARTICIPANTS)
text
C0000970 (UMLS CUI [1,1])
C0750480 (UMLS CUI [1,2])
C0994475 (UMLS CUI [1,3])
C2348070 (UMLS CUI [1,4])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
Item
OTHER NSAID (ALL PARTICIPANTS)
text
C0205394 (UMLS CUI [1,1])
C0003211 (UMLS CUI [1,2])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
IBUPROF
Code List
OTHER NSAID (ALL PARTICIPANTS)
CL Item
No (N)
C1298908 (UMLS CUI [1,1])
CL Item
Yes (Y)
C1705108 (UMLS CUI [1,1])
OTHNSASP
Item
OTHER NSAID NAME (ALL PARTICIPANTS)
string
C0205394 (UMLS CUI [1,1])
C0003211 (UMLS CUI [1,2])
C0027365 (UMLS CUI [1,3])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
OTHNSAPL
Item
OTHER NSAID PILLS/DAY (ALL PARTICIPANTS)
text
C0205394 (UMLS CUI [1,1])
C0003211 (UMLS CUI [1,2])
C0750480 (UMLS CUI [1,3])
C0994475 (UMLS CUI [1,4])
C2348070 (UMLS CUI [1,5])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
Item
HOW LONG ON NSAID AT LEAST 5 TIMES/WEEK (ALL PARTICIPANTS)
text
C0449238 (UMLS CUI [1,1])
C0003211 (UMLS CUI [1,2])
C0205272 (UMLS CUI [1,3])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
HOWLONG
Code List
HOW LONG ON NSAID AT LEAST 5 TIMES/WEEK (ALL PARTICIPANTS)
CL Item
Less than 1 year (1)
C0439092 (UMLS CUI [1,1])
C0439234 (UMLS CUI [1,2])
CL Item
More or equal to 1 and less than 3 years (2)
C0439092 (UMLS CUI [1,1])
C0205437 (UMLS CUI [1,2])
C0439234 (UMLS CUI [1,3])
CL Item
More or equal to 3 and less than 7 years (3)
C0439092 (UMLS CUI [1,1])
C0205441 (UMLS CUI [1,2])
C0439234 (UMLS CUI [1,3])
CL Item
More or equal to 7 years (4)
C0439093 (UMLS CUI [1,1])
C0205441 (UMLS CUI [1,2])
C0439234 (UMLS CUI [1,3])
Item
ACETAMINOPHEN (500 MG) (ALL PARTICIPANTS)
text
C0000970 (UMLS CUI [1,1])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
IBUPROF
Code List
ACETAMINOPHEN (500 MG) (ALL PARTICIPANTS)
CL Item
No (N)
C1298908 (UMLS CUI [1,1])
CL Item
Yes (Y)
C1705108 (UMLS CUI [1,1])
NSAIDSTIME
Item
YEARS FROM RANDOMIZATION TO DATE OF STUDY VISIT WHERE NSAID DATA WAS COLLECTED (ALL PARTICIPANTS)
float
C0439234 (UMLS CUI [1,1])
C0034656 (UMLS CUI [1,2])
C0008972 (UMLS CUI [1,3])
C1320303 (UMLS CUI [1,4])
C0003211 (UMLS CUI [1,5])
C0010995 (UMLS CUI [1,6])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
Ritorna all'inizio della pagina